Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof

Abstract

The invention discloses a new clause of a five membered heterocylic ring compounds of general formula I and its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and/or free radicals in the body cells.

1 . A compound represented by formula (I) and its pharmaceutically or cosmetically acceptable salts  
     
       
         
         
             
             
         
       
     
     wherein, 
 R 1  is hydrogen or selected from linear or branched (C 1 -C 12 ) alkyl, (C 2 -C 12 ) alkenyl, (C 3 -C 7 ) cycloalkyl, (C 5 -C 7 ) cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl and wherein one or more heteroatoms when present are independently selected from O, N, or S and is optionally substituted, wherein the substituents are selected from a first group consisting of halogen, hydroxy, nitro, cyano, amino, oxo and oxime or from a second group consisting of linear or branched (C 1 -C 8 ) alkyl, (C 3 -C 7 ) cycloalkyl, alkylcycloalkyl, perhaloalkyl, perhalocycloalkyl, aryl, aralkyl, alkylaryl, alkylheteroaryl, aralkoxylalkyl, perhaloaryl, alkylheterocycloalkyl, heterocyclyloalkyl, perhaloheterocyclyloalkyl, heteroaryl, heteroaralkyl, alkylaryl, perhaloheteroaryl, acyl, alkoxyalkyl, thioalkyl and thioaryl, wherein the substitutents from said second group are optionally substituted by R 10  and are optionally and independently bridged by —(CO)O—, —(CO)NH—, —NH—, —NR 8 —, —O—, —S—, —(SO)—, —(SO 2 ), —(SO 2 )NH—, or —NH(CO)—;  
 Y is selected from the group consisting of null, (C 1 -C 12 ) alkyl-Z or (C 2 -C 12 ) alkyl, wherein Z is selected from sulfur, oxygen or nitrogen;  
 A and B are independently selected from NH, NR6, sulfur, oxygen or carbon to form a heteroaromatic ring system;  
 R 2 , R 3  and R 4  are independently selected from a first group consisting of hydrogen, halogen, NO 2 , N═C(R 8 )(R 9 ), —NR 8 R 9 , —OR 8 , perhaloalkyl, —(CO)NR 8 R 9 , —(CO)R 8 , —(CO)OR 8 , —O(CO)R 8 , —NH(CO)R 8  or from a second group consisting of linear or branched (C1-C12)alkyl, (C2-C12)alkenyl, (C3-C7)cycloalkyl, (C5-C7)cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, wherein one or more members of said second group when present are optionally substituted by R10 and wherein one or more heteroatoms when present are independently selected from O, N, or S;  
 R 5  is null or selected from the group consisting of linear or branched (C 1 -C 12 )alkyl, (C 2 -C 12 )alkenyl, (C 3 -C 7 )cycloalkyl, (C 5 -C 7 )cycloalkenyl, bicycloalkyl; CH 2 (CO)R 7 , CH 2 (CO)NHR 8 , CH 2 (CO)NR 8 R 9 , and CH 2 (CO)OR 7  which are optionally substituted by R 10 ;  
 R 6  and R 7  are independently selected from the group consisting of linear or branched (C 1 -C 8 ) alkyl, (C 3 -C 7 )cycloalkyl, alkylcycloalkyl, perhaloalkyl, perhalocycloalkyl, aryl, aralkyl, alkylaryl, alkylheteroaryl, aralkoxylalkyl, perhaloaryl, alkylheterocycloalkyl, heterocyclyloalkyl, perhaloheterocyclyloalkyl, heteroaryl, heteroaralkyl, alkylaryl, perhaloheteroaryl, acyl, benzoyl, alkoxyalkyl, thioalkyl and thioaryl wherein members of said group are optionally substituted by R 10 ;  
 R 8  and R 9  are independently selected from the group consisting of linear or branched (C 1 -C 12 )alkyl, alkoxyaryl, alkoxyalkyl, alkoxycycloalkyl, alkoxyaryl, perhaloalkyl, (C 2 -C 12 )alkenyl, (C 3 -C 7 )cycloalkyl, perhalocycloalkyl, haloheterocycloalkyl, cyanoheterocycloalkyl, perhaloheterocycloalkyl, (C 5 -C 7 )cycloalkenyl, bicycloalkyl, bicycloalkenyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, perhaloaryl, perhaloheteroaryl wherein substituents of said group are optionally substituted by R 10 ;  
 R 10  is selected from halogen, hydroxy, nitro, cyano, amino, oxo, perhaloalkyl(C 1 -C 6 ), or oxime;  
 X is selected from group comprising of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF 4   −  and PF 6   −   
 provided when the groups/substituents are present on same or adjacent carbon or nitrogen atoms they together may optionally form a five or a six or a seven membered ring optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from O, N, or S.  
 
   
   
       2 . The compound as claimed in  claim 1 , wherein said pharmaceutically/cosmetically acceptable salts are salts of the carboxylic acid selected from alkali metal salts and alkaline earth metal salts; salts of organic bases selected from lysine, arginine, guanidine, diethanolamine and choline; ammonium or substituted ammonium salts, aluminium salts; or acid addition salts selected form the group consisting of sulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzensulfonates, ascorbates, glycerophosphates and ketoglutarates.  
   
   
       3 . A compound as claimed in  claim 1 , wherein R 1  is a substituted or unsubstituted group selected from linear or branched (C 1 -C 12 )alkyl, (C 3 -C 7 )cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein one or more heteroatoms when present are independently selected from O, N, or S.  
   
   
       4 . A compound as claimed in  claim 1 , wherein Y is selected from the group consisting of null (C 1 -C 8 ) alkyl-Z and (C 1 -C 8 ) alkyl, wherein Z is selected from sulfur, oxygen or nitrogen.  
   
   
       5 . A compound as claimed in  claim 1 , wherein A and B are independently selected from NH and NR 6 .  
   
   
       6 . A compound as claimed in  claim 1 , wherein R 2 , R 3  and R 4  are independently selected from the group consisting of hydrogen, halogen, NO 2  and perhaloalkyl.  
   
   
       7 . A compound as claimed in  claim 1 , wherein R 5  is either null or selected from the group CH 2 (CO)R 7  and CH 2 (CO)NHR 8 , optionally substituted by R 10 .  
   
   
       8 . A compound as claimed in  claim 1 , wherein X is halide.  
   
   
       9 . A compound as claimed in  claim 1 , which is selected from the group consisting of the following compound or pharmaceutically acceptable salts thereof: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide;    b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium dibromide;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3 {(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3 {(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazole-5-yl]pyridinium chloride;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride;    bbb) 1-(2-thien-2′-yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo pyridinium chloride;    ccc) 1-(2-thien-2′-yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline.    
   
   
       10 . A process for the preparation of the compound of general formula (I) as defined in  claim 1 , which comprises the steps of: 
 (a) preparing the corresponding 1,3 diketo compound by reacting unsubstituted/substituted acetyl pyridines with alkyl/aryl esters in a suitable base or by reacting unsubstituted/substituted aryl esters with unsubstituted/substituted aryl methyl ketone in a suitable base;    (b) cyclizing of the product obtained in step (a) and optionally;    (c) quaternizing the substituted pyridine obtained in step (b), with a quaternizing agent in an alcoholic and/or high boiling solvent under reflux for 6-48 hrs. to give the desired compound.    
   
   
       11 . A pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of general formula (I), as defined in  claim 1  or pharmaceutically acceptable salt(s) thereof in admixture with a pharmaceutically acceptable carrier, diluent, solvent or excipient.  
   
   
       12 . A pharmaceutical composition as claimed in  claim 11 , in the form of an oral formulation.  
   
   
       13 . A pharmaceutical composition as claimed in  claim 11 , wherein said acceptable carrier, diluent, solvent or excipient is selected from group comprising of starch, lactose, polyvinyl pyrolidone (K-30), talc and magnesium stearate.  
   
   
       14 . A pharmaceutical composition as claimed in  claim 11  in the form of a parenteral formulation.  
   
   
       15 . A method for the preparation of a parenteral formulation as claimed in  claim 14 , which comprises dissolving one or more compounds of general formula (I), as defined in  claim 1 , in polyethylene glycol 400 and diluting the solution so obtained, with an isotonic solution or water to a desired concentration.  
   
   
       16 . A pharmaceutical composition as claimed in  claim 11 , in the form of a lotion, oral rinse and toothpaste.  
   
   
       17 . A pharmaceutical composition as claimed  claim 11  wherein said compound is selected from the group consisting of: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrozol-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof.    
   
   
       18 . A method for treating a mammal for diseases, caused by the accumulation of AGE, by breaking a preformed AGE, within said mammal, which comprises, administering an effective amount of a compound of formula (I) as defined in  claim 1 , either singly, or in combination with other drugs for antidiabetic therapy with a pharmaceutically acceptable carrier, diluent or excipient.  
   
   
       19 . The method as claimed in  claim 18  wherein the disease caused to be treated is selected from diabetes and aging related vascular or neurovascular disorders.  
   
   
       20 . The method as claimed in  claim 18  wherein the disease caused to be treated thereby is selected from diabetes and aging related vascular or neurovascular disorders.  
   
   
       21 . The method as claimed in  claim 18 , wherein the disease caused to be treated, is selected from the group consisting of nephrological disorder, neurological disorder, atherosclerosis, retinal disorder, inflammatory disorder, immunological disorder, oxidative stress, non-enzymatic browning of oral cavity, endothelial or other organ dysfunction and growth impairment.  
   
   
       22 . The method as claimed in  claim 18 , wherein the disease caused to be treated is selected from the group consisting of alzheimer disease, restenosis, abnormal tissue hindrance in peritoneal dialysis and erectile dysfunction.  
   
   
       23 . The method as claimed in  claim 18 , wherein said compound is selected from the group comprising of: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrozol-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof.    
   
   
       24 . A method for treating a mammal, to inhibit accumulation of AGE, by breaking AGE, which comprises, administering to a mammal in need thereof, an effective amount of a compound general formula (I), as defined in  claim 1 , either singly or in combination with other drugs for antidiabetic thereby in a pharmaceutically acceptable carrier, diluent or excipient.  
   
   
       25 . The method as claimed in  claim 24  wherein disease caused to be treated thereby is selected from a nephrological disorder, neurological disorder, atherosclerosis, retinal disorder, inflammatory disorder, immunological disorder, oxidative stress, non-enzymatic browning of oral cavity, endothelial or other organ dysfunction and growth impairment.  
   
   
       26 . The method as claimed in  claim 24  wherein the disease caused to be treated thereby is selected from alzheimer disease, restenosis, abnormal tissue hindrance in peritoneal dialysis and erectile dysfunction.  
   
   
       27 . The method as claimed in  claim 24 , wherein said compound is selected from the group consisting of: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrozol-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof;    
   
   
       28 . A method for treating and/or preventing diseases caused by accumulation of AGE in a mammal, by inhibiting the formation of AGE, within said mammal, which comprises, administering an effective amount of a compound of formula (I) as defined in  claim 1 , either singly, or in combination with other drugs for antidiabetic therapy in a pharmaceutically acceptable carrier, diluent or excipient.  
   
   
       29 . The method as claimed in  claim 28 , wherein the disease caused to be treated and/or prevented thereby is selected from diabetes and aging related vascular and neurovascular disorders.  
   
   
       30 . The method as claimed in  claim 28 , wherein the disease caused to be treated and/or prevented thereby is selected from alzheimer disease, restenosis, abnormal tissue hindrance in peritoneal dialysis and erectile dysfunction.  
   
   
       31 . The method as claimed in  claim 28 , wherein the disease caused to be treated and/or prevented thereby is selected from nephrological disorder, neurological disorder, atherosclerosis, retinal disorder, inflammatory disorder, immunological disorder, oxidative stress, non-enzymatic browning of oral cavity, endothelial or other organ dysfunction and growth impairment.  
   
   
       32 . The method as claimed in  claim 28  wherein said compound is selected from the group consisting of: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide 
 or a pharmaceutically acceptable salt thereof;  
   b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrozol-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethy)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof;    
   
   
       33 . (canceled)  
   
   
       34 . The method as claimed in  claim 29 ,  30  or  31 , wherein said compound is selected from the group consisting of: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)-methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrozol-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof;    
   
   
       35 . A method of scavenging free radical in the body cells comprising administering to a mammal in need of scavenging free radical from its body cells an effective amount of a compound of general formula (I) as defined in  claim 1 , either singly or in combination in other antioxidants in a pharmaceutically acceptable carrier, diluent or excipient.  
   
   
       36 . The method as claimed in  claim 35 , wherein said compound is selected from the group consisting of; 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide 
 or a pharmaceutically acceptable salt thereof;  
   b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethyl)-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof;    
   
   
       37 . A method of treating diseases caused by accumulation of free radicals in the body cells of a mammal comprising treating a mammal affected by such disease with an effective amount of a compound of formula (I) as defined in  claim 1 .  
   
   
       38 . The method as claimed in  claim 37  wherein said compound is selected from the group consisting of: 
 a) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    b) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenylmethyl)oxazol-5-yl pyridinium bromide or a pharmaceutically acceptable salt thereof;    c) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(2-thien-2′-yl)-2-oxoethyl pyridinium-4-thio}methyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    d) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3-{1-(3,5-dimethylpyrazol-1-yl)methyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    e) 1-(2-thien-2′-yl-2-oxoethyl)-3-[{3-phenylmethyl}-1-{2-pyridyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    f) 1-(2-thien-2′-yl-2-oxoethyl)-3-[3{(3,5-dimethylpyrazol-1-yl)methyl-1-pyridyl}pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    g) 1-[2-(cyclopropylamino)-2-oxoethyl]3-[3-{(3,5-dimethylpyrazol-1-yl)methyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    h) 1-{2-(4-nitro-2-thienyl)-2-oxoethyl}-3-[3{(3,5-dimethylpyrazol-1-yl)ethyl}-pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    i) 1-(2-cyclopropylamino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    j) 3,5-bis-[1-(2-thien-2′-yl-2-oxoethyl)-pyridinium-3-yl]-pyrazole dibromide and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof;    k) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    l) 1-(2-(5′-methyl-2-thienyl)-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    m) 1-(2-thien-2′-yl-2-oxoethyl)3-[1-phenyl,3-{(3,5-dimethylpyrazol-1-yl)methyl)}pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    n) 1-(2-phenyl-2-oxoethyl)-3-[(3-phenylmethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    o) 1-(2-cyclopropylamino-2-oxoethyl)3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    p) 1-(2-(4-benzyl-1-piperidinyl)-2-oxoethyl)3-[(3-phenoxymethyl)pyrazol-5-yl]-pyridinium bromide or a pharmaceutically acceptable salt thereof;    q) 1-(2-phenyl-2-oxoethyl)-3-[(3-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]-pyridinium chloride or a pharmaceutically acceptable salt thereof;    r) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3,-(3,5-dimethylpyrazol-1-yl)methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    s) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    t) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    u) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    v) 1-(2-phenyl-2-oxoethyl)-3-[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    w) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    x) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    y) 1-[2-(1-adamantylamino)-2-oxoethyl]-3-[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    z) 1-(2-phenyl-2-oxoethyl)-3-[{3-(3,5-dimethylpyrazol-1-yl)methyl)}1-phenyl-pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aa) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl)-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    bb) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3[(3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    cc) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    dd) 1-(2-(4-nitro-2-thienyl)-2-oxoethyl)-3-[(1-phenyl-3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ee) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ff) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethyl)-1-yl)methyl)pyrazole-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    gg) 1-(2-(5-chloro-2-thienyl)-2-oxoethyl)-3-[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    hh) 1-(2-phenyl-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ii) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    jj) 1-(2-cyclopropylamino-2-oxoethyl)-3-[(1-phenyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    kk) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-phenyl-3-(2-cyclohexylethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    ll) 1-(2-thien-2′-yl-2-oxoethyl)-3-[(1-cyclohexyl-3-phenoxymethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    mm) 3-[(3-phenylmethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    nn) 3-[(3-phenoxymethyl)pyrazol-5-yl]pyridine hydrochloride or a pharmaceutically acceptable salt thereof;    oo) 3-[(3,5-dimethylpyrazol-1-yl-methyl)pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    pp) 3-[3-(2-cyclohexyl-ethyl)-pyrazol-5-yl]pyridine or a pharmaceutically acceptable salt thereof;    qq) 1-(2-napthyl-2-oxoethyl)-3[(3-phenoxymethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    rr) 1-(phenylmethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ss) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3(-1-naphthyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    tt) 1-(2-phenyl-2oxoethyl)-3[3(thienyl-2-yl-methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    uu) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[3(2-phenylethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    vv) 1-(2-(5-methyl 2-thienyl)-2-oxoethyl)-3-[3-(3-phenoxypropyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    ww) 1-(isopropyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    xx) 1-(2-(5-methyl-2-thienyl)-2-oxoethyl)-3-[(3-thiophenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    yy) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-(N-methyl-indole-3-yl methyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    zz) 1-(2-napthyl-2-oxo-ethyl)-3[(3-methyl)pyrazol-5-yl]pyridinium bromide or a pharmaceutically acceptable salt thereof;    aaa) 1-(2-(1,4 benzodioxane-6-yl-amino-2-oxoethyl)-3[(3-phenylmethyl)pyrazol-5-yl]pyridinium chloride or a pharmaceutically acceptable salt thereof;    bbb) 1-(2-thien-2′-yl-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]-5 bromo-pyridinium chloride or a pharmaceutically acceptable salt thereof;    ccc) 1-(2-thien-2-′yl)-2-oxoethyl)-3[(3-phenyl)pyrazol-5-yl]quinolinium chloride or a pharmaceutically acceptable salt thereof and    ddd) 3-[(3-phenyl)pyrazol-5-yl)]quinoline or a pharmaceutically acceptable salt thereof;    
   
   
       39 . The method as claimed in  claim 37 , wherein the diseases caused to be treated are selected from the group consisting of: 
 a) Neurodegenerative disorders,    b) Diabetes and Diabetic Vascular Disorders,    c) Intestinal Diseases,    d) Liver Diseases,    e) Cancers,    f) Cardiac Diseases,    g) Opthalmic Disorders,    h) HIV Disease,    i) Respiratory Disease and    j) Renal Diseases    
   
   
       40 - 65 . (canceled)  
   
   
       66 . Use of a compound as defined in  claim 1  in the preparation of a dialysis fluid useful for peritoneal dialysis of a diabetic patient.